Shares in Verona Pharma plc have rocketed after the UK respiratory disease specialist raised $200m in an oversubscribed private placement and subscription that will more than cover the costs of the late-stage program for its chronic obstructive pulmonary disease drug ensifentrine.
The fundraise, the proceeds of which are expected to total $183m after deducting placement agent fees and expenses, comprises a...






